Author + information
We sought to investigate whether high platelet reactivity affects clinical outcomes of patients with drug eluting stents (DESs) implantation.
All enrolled individuals treated with DESs implantation were evaluated by PL-11, using sequentially platelet counting method. The primary end point was the occurrence of definite and probable stent thrombosis at two years. The secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), including all cause death, spontaneous myocardial infarction (MI), target vessel revascularization (TVR), and ischemic stroke.
A total of 1331 consecutive patients were enrolled at six Chinese centers. There were 91 patients (6.8%) identified with high platelet reactivity (HPR) on aspirin, and 437 patients (32.9%) with HPR on clopidogrel. At 2-year follow-up, the incidence of stent thrombosis was significantly higher in patients with HPR on aspirin (9.9% vs. 0.4%, p<0.001), and HPR on clopidogrel (3.0% vs. 0.1%, p<0.001). There were increased MACCE in the HPR on aspirin group (16.5% vs. 8.5%, p=0.021), mainly driven by the higher all cause death (7.7% vs. 1.6%, p=0.002) and MI (9.9% vs. 1.9%, p<0.001) in the HPR on aspirin group. Similarly, the rate of MACCE was higher in the HPR on clopidogrel group (12.4% vs. 7.4%, p=0.004). No differences in all bleeding and hemorrhagic stroke were observed.
The present study demonstrated that high platelet reactivity on both aspirin and clopidogrel were associated with incremental stent thrombosis following DESs implantation.